人卵巢癌細(xì)胞NIH:OVCAR-3

??【編號】：NIH:OVCAR-3

??【名稱】：人卵巢癌細(xì)胞NIH:OVCAR-3

??【規(guī)格】：株

??【價(jià)格】：2300

　　人卵巢癌細(xì)胞

　　細(xì)胞名稱：NIH/3T3小鼠胚胎細(xì)胞

　　描述：NIH-OVCAR-3細(xì)胞由T.C.Hamilton在1982年建系。取材于患進(jìn)行性卵巢腺癌病人的惡性腹水。與107細(xì)胞聯(lián)合皮下接種５只裸鼠21天后全部成瘤。 NIH-OVCAR-3是研究卵巢癌藥物抗性的一個合適的模型系統(tǒng)且由于存在激素受體，這對于激素治療的評估或許是有用的。

　　動物種別：人

　　性別：女

　　組織來源：卵巢腺癌

　　形態(tài)：上皮細(xì)胞

　　培養(yǎng)基和添加劑：RPMI-1640(GIBCO,貨號31800022, 添加NaHCO3 1.5g/L, glucose 2.5g/L, Sodium Pyruvate 0.11g/L)，90%；添加0.01毫克/毫升牛胰島素，80%；優(yōu)質(zhì)胎牛血清，20%。氣相：空氣，95%；二氧化碳，5%。溫度：37攝氏度。

　　供應(yīng)限制：A。僅供研究之用。

　　REFERENCE：Hamilton TC , et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576 Hamilton TC , et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin.www.atcc360.com。 Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867 Rogan AM , et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095 Hamilton TC , et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272 Green JA , et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194 Caffrey PB , Frenkel GD . Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444 Hamilton TC , et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258 Godwin AK , et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364 Chang K , Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591 Omelyanenko V , et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998.

上一篇：小鼠胚胎細(xì)胞NIH/3T3		下一篇：人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞NK-9

人卵巢癌細(xì)胞

產(chǎn)品明細(xì)

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關(guān)產(chǎn)品

人卵巢癌細(xì)胞

產(chǎn)品明細(xì)

熱銷產(chǎn)品 新品上架

產(chǎn)品推薦 相關(guān)產(chǎn)品

　　人卵巢癌細(xì)胞

熱銷產(chǎn)品新品上架

產(chǎn)品推薦相關(guān)產(chǎn)品